The Challenges of Treating FLT3-ITD AML
Mark J. Levis, MD, PhD, discusses the difficulty of treating a patient with a FLT3-ITD mutation in acute myeloid leukemia.
Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the difficulty of treating a patient with a FLT3-ITD mutation in acute myeloid leukemia (AML).
Clinical Pearls:
- While an AML patient with a low white blood cell count can be maintained with transfusions and antibiotics, the population of patients with a FLT3-ITD mutation are difficult to palliate
- The majority of patients with a high white blood cell count and a FLT3-ITD mutation can be treated into remission but they will eventually relapse
- Physicians attempt to keep these patients in remission long enough to be able to get a transplant
Recent Videos
Related Content
Selection of Next-Gen BTK in CLL Limited By Lack of Direct Comparison
February 4th 2025Article
During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK inhibitor therapies acalabrutinib and zanubrutinib in patients with chronic lymphocytic leukemia who received 1 prior line of therapy in the second article of a 2-part series.
Read More
